Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02974803 : Concurrent Dabrafenib and Trametinib With Sterotactic Radiation in Patients With BRAF Mutation-Positive Malignant Melanoma and Brain Metastases
PhasePhase 2
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- Histologically confirmed melanoma metastatic to brain and determined to be BRAF V600

- Age = 18 years.

- Karnofsky Performance Status of 70-100 (Appendix I).

- Patients must have a life expectancy of at least 12 weeks.

- Presence of measurable disease (i.e. present with at least one measurable CNS lesion
per RECIST 1.1).

- Presence of 1-10 brain metastases as confirmed on a thin slice axial T1
post-gadolinium MRI sequence. The maximum diameter of a single brain lesion should be
= 4 cm and presence of a measurable lesion = 1cm based on baseline MRI of brain.

- All CNS metastases amenable to single fraction SRS and or fractionated SRS.
Hemorrhagic lesions are allowed if the treating radiation oncologist deems the lesion
amenable to focal SRS.

- Able to swallow and retain oral medication and must not have any clinically
significant gastrointestinal abnormalities that may alter absorption such as
malabsorption syndrome or major resection of the stomach or bowels.

- Laboratory requirements (within 14 days prior to registration):

- ANC = 1.2 x 10^9/L

- Hemoglobin = 90 g/L

- Platelet count = 100 x 10^9/L

- PT/INR & PTT = 1.3 x ULN

- Total bilirubin = 1.5 x ULN

- AST and ALT = 2.5 x ULN

- Serum creatinine or = 1.5 x ULN or Creatinine Clearance = 50 ml/min (calculated
by Cockcroft and Gault)

- LVEF = LLN (within 28 days prior to registration)

- No prior treatment with a BRAF inhibitor or MEK inhibitor.

- No known ocular or primary mucosal melanoma.

- No prior systemic anti-cancer treatment within the last 2 weeks preceding the
frist dose of dabrafenib and trametinib. Patients must have recoved from clinical
manifestations of toxicity related to prior systemic therapy and have adequate
washout as follows: Longest of one of the following:

- two weeks

- 5 half-lives for investigational agents

- Standard cycle length of standard therapies

- Prior systemic treatment in the adjuvant setting is allowed.

- No current use of a prohibited medication as described in section 7.2.

- No history of malignancy with confirmed activating RAS mutation at any time.

- No history of malignancy other than disease under study within 3 years of study

- No leptomeningeal metastases or metastases causing spinal cord compression that
are symptomatic or untreated or not stable for = 3 months. Subjects on stable
dose of corticosteroids > 2 weeks or who have been off of corticosteroids for at
least 2 weeks can be enrolled with approval of CCTG.

- No serious or unstable pre-existing medical conditions, psychiatric disorders or
other conditions that could interfere with the subject's safety, obtaining
informed consent or compliance with study procedures.

- No history of Hepatitis B Virus or Hepatitis C Virus infection

- No history or evidence of cardiovascular risk No history or current
eveidence/risk of retinal vein occlusion or central serous retinopathy

- No known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
chemically related to the study treatments, their excipients, and/or dimethyl

- No pregnant or lactating women.

- No hisotry of interstitial lung disease or active pneumonitis.

- Presence of any one brain metastases >4cm in maximal diameter, and/or presence of
brain metastase of less than 1cm.

- No prior whole brain radiation

- No brainstem metastses

- No contrindications to MRI and/or Gadolinimum contrast or sterotactic brain
radiation therapy.
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557